Novel approaches to targeting BRD4

...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Reply New Message

Prev Message Back To Forum Threaded View Next Message

BearDownAZ

Rank: President [?]

Points: 25003 [?]

Votes: 68 Score: 4.5 [?]

Your Vote:

Please Log In to Vote

Did you know? You can earn activity points by filling your profile with information about yourself (what city you live in, your favorite team, blogs etc.)

Novel approaches to targeting BRD4

posted on Dec 14, 2017 11:24AM

"Novel approaches to targeting BRD4" authored by Zenith's Olesya A.Kharenko and Henrik C.Hansen was published earlier this year in Drug Discovery Today: Technologies. It is a review focusing on recent advances in the use of alternatives to reversible BET inhibitors: 1) Strategies/drugs that promote BRD4 protein degradation; and 2) Irreversible small-molecule inhibitors of BRD4

https://www.ncbi.nlm.nih.gov/pubmed/29233295

https://www.sciencedirect.com/science/article/pii/S1740674916300427

4 Recommendations

Reply New Message

Prev Message Back To Forum Threaded View Next Message

Please to post a reply